For example, overactivation of the RAAS (Singh and Mehta, 2003) and insulin resistance (Ormazabal et al., 2018) alter systemic lipid metabolism, leading to the development of atherogenic dyslipidemia. The gene discussed is INS; the disease is metabolic syndrome.